Special report
Resolved and unresolved issues in the prevention and treatment of coronary artery disease: A workshop consensus statement,☆☆

https://doi.org/10.1016/0002-8703(91)90694-DGet rights and content

Abstract

Advances in cardiovascular research during the past two decades have resulted in an improved understanding of the chain of events that lead to end-stage coronary artery disease. These developments have been paralleled by therapeutic advances that now make it possible to intervene at virtually every stage in the development of advanced cardiac disease, from asymptomatic persons at risk of developing coronary atherosclerosis to patients with end-stage heart failure. By interrupting this chain of events, perhaps at multiple sites, it may be possible to prevent or slow the development of symptomatic heart disease and hopefully prolong life. Many opportunities exist for obtaining further information regarding the underlying pathophysiology, the fundamental mechanisms of action of interventions designed to prevent and/or treat the development of myocardial ischemia and cardiac failure and for effecting favorably the natural history of various forms of heart disease.

References (123)

  • VJ Dzau

    Cardiac renin-angiotensin system molecular and functional aspects

    Am J Med

    (1988)
  • WS Aronow et al.

    Usefulness of echocardiographic left ventricular hypertrophy in predicting new coronary events and atherothrombotic brain infarction in patients over 62 years of age

    Am J Cardiol

    (1988)
  • FM Fouad et al.

    Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa

    Am J Cardiol

    (1982)
  • FH Leenen et al.

    Vasodilators and regression of left ventricular hypertrophy: hydralazine versus prazosin in hypertensive humans

    Am J Med

    (1987)
  • HO Ventura et al.

    Cardiovascular effects and regional blood flow distribution associated with angiotensin converting enzyme inhibition (captopril) in essential hypertension

    Am J Cardiol

    (1985)
  • KL Neuhaus et al.

    Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator

    J Am Coll Cardiol

    (1989)
  • K Przyklenk et al.

    Nifedipine administered post-reperfusion ablates systolic contractile dysfunction of postischemic “stunned” myocardium

    J Am Coll Cardiol

    (1989)
  • PM Mehta et al.

    Functional infarct expansion, left ventricular dilation and iso-volumic relaxation time following coronary occlusion: a two-dimensional echocardiographic study

    J Am Coll Cardiol

    (1988)
  • J Xiang et al.

    Effects of converting enzyme inhibitors: ramipril and enalapril on peptide action and sympathetic neurotransmission in the isolated heart

    Eur J Pharmacol

    (1985)
  • HM McAlpine et al.

    Neuroendocrine changes in acute myocardial infarction

    Am J Med

    (1988)
  • CE Hock et al.

    Preservation of ischemic myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarction

    Am Heart J

    (1985)
  • HF Weisman et al.

    Myocardial infarct expansion, infarct extension and reinfarction: pathophysiologic concepts

    Prog Cardiovasc Dis

    (1987)
  • HA Tyroler

    Lowering plasma cholesterol levels decreases risk of coronary heart disease: an overview of clinical trials

  • Lipid Research Clinics Program

    The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

    JAMA

    (1984)
  • Lipid Research Clinics Program

    The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering

    JAMA

    (1984)
  • BG Brown et al.

    Niacin or lovastatin, combined with colestipol, regress coronary atherosclerosis and prevent clinical events in men with elevated apolipoprotein B [Abstract]

    Circulation

    (1989)
  • JF Brensike et al.

    Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study

    Circulation

    (1984)
  • DH Blankenhorn et al.

    Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts

    JAMA

    (1987)
  • The Expert Panel

    Report of the National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults

    Arch Intern Med

    (1988)
  • L Goldman et al.

    Relative impact of targeted versus population-wide cholesterol interventions on the incidence of coronary heart disease. Projections of the Coronary Heart Disease Policy Model

    Circulation

    (1989)
  • Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction

    (February 27, 1990)
  • SM Grundy et al.

    The place of HDL in clinical management. A perspective from the National Cholesterol Education Program

    Arch Intern Med

    (1989)
  • D Steinberg et al.

    Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity

    N Engl J Med

    (1989)
  • GJ Schroepfer et al.

    5α-Cholest-8(14)-en-3β-ol-15-one lowers serum cholesterol and induces profound changes in the levels of lipoprotein cholesterol and apoproteins in monkeys fed a diet of moderate cholesterol content

  • TE Carew et al.

    Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit

  • RB Shekelle et al.

    Diet, serum cholesterol and death from coronary heart disease: the Western Electric Study

    N Engl J Med

    (1981)
  • S Shea et al.

    Treatment of hypertension and its effect on cardiovascular risk factors: data from the Framingham Heart Study

    Circulation

    (1985)
  • T Pollare et al.

    A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension

    N Engl J Med

    (1989)
  • Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressure averaging 90 through 114 mm Hg

    JAMA

    (1970)
  • Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the multiple Risk Factor Intervention Trial

    Am J Cardiol

    (1985)
  • The effect of antihypertensive drug treatment on mortality in the presence of resting electrocardiographic abnormalities at baseline. The HDFP experience

    Circulation

    (1984)
  • The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure

    1984 Report

    Arch Intern Med

    (1984)
  • T Sugimoto et al.

    The incidence of treated and stage renal disease in the eastern United States

    Am J Public Health

    (1984)
  • AS Krolewski et al.

    Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus

    N Engl J Med

    (1988)
  • CE Mogensen

    Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes

    N Engl J Med

    (1984)
  • S Anderson et al.

    Therapeutic implications of converting-enzyme inhibitors in renal disease

    Am J Kidney Dis

    (1987)
  • BJ Silver et al.

    Platelet-derived growth factor synthesis in mesangial cells: induction by multiple peptide mitogens

  • ML Purkerson et al.

    N-desulfated/acetylated heparin ameliorates the progression of renal disease in rats with subtotal renal ablation

    J Clin Invest

    (1988)
  • JJ Castellot et al.

    Heparin and glomerular epithelial cell-secreted heparin-like species inhibit mesangial cell proliferation

    Am J Pathol

    (1985)
  • CC Cowie et al.

    Disparities in incidence of diabetic end stage renal disease according to race and type of diabetes

    N Engl J Med

    (1989)
  • Cited by (0)

    This article is based on the consensus reached by participants at a workshop entitled, “Frontiers of cardiovascular therapy and cardiac protection: Resolved and unresolved issues,” held January 8–10, 1989 and subsequently updated. Cochairmen: Eugene Braunwald, MD, and Victor Dzau, MD, Boston, Mass. Participants: Lewis C. Becker, MD, Baltimore, Md.; Roland C. Blantz, MD, San Diego, Calif.; B. Greg Brown, MD, PhD, Seattle, Wash.; Kanu Chatterjee, MB, FRCP, San Francisco, Calif.; Aram V. Chobanian, MD, Boston, Mass.; A. Richard Christlieb, MD, Boston, Mass.; Robert J. Cody, MD, Columbus, Ohio; Jay N. Cohn, MD, Minneapolis, Minn.; John E. Deanfield, MD, MRCP, London, England; Curt D. Furberg, MD, PhD, Winston-Salem, N.C.; Valentin Fuster, MD, New York, N.Y.; Lee Goldman, MD, Boston, Mass.; Sidney Goldstein, MD, Detroit, Mich.; DeWitt Goodman, MD, New York, N.Y.; Sidney O. Gottlieb, MD, Baltimore, Md.; Charles H. Hennekens, MD, Boston, Mass.; Donald Hunninghake, MD, Minneapolis, Minn.; William B. Kannel, MD, MPH, Boston, Mass.; J. Ward Kennedy, MD, Seattle, Wash.; Robert A. Kloner, MD, PhD, Los Angeles, Calif.; Beverly H. Lorell, MD, Boston, Mass.; Joe M. McCord, PhD, Mobile, Ala.; Joel Morganroth, MD, Philadelphia, Pa.; Bertram Pitt, MD, Detroit, Mich.; Leopoldo Raij, MD, Minneapolis, Minn.; Robert Roberts, MD, Houston, Texas; Jean-Lucien Rouleau, MD, FRCP, Montreal, Canada; Edmund H. Sonnenblick, MD, Bronx, N.Y.; Herman A. Tyroler, MD, Chapel Hill, N.C.; Paul M. Vanhoutte, MD, PhD, Houston, Texas; Michael A. Weber, MD, Long Beach, Calif.; Harry Wesseling, MD, PhD, Groningen, The Netherlands; Harvey D. White, MB, ChB, FRACP, Auckland, New Zealand; James T. Willerson, MD, Houston, Texas; and David O. Williams, MD, Providence, R.I.

    ☆☆

    The workshop on which this article is based was supported by an educational grant from Bristol-Myers-Squibb Corporation, Princeton, N. J.

    View full text